Cepacia Syndrome in Cystic Fibrosis: A Systematic Review of the Literature and Possible New Perspectives in Treatment [PDF]
AbstractBackgroundCepacia syndrome (CS) is an acute, necrotizing pneumonia with a high mortality rate, occurring in patients with cystic fibrosis (CF) infected with Burkholderia cepacia complex (BCC). Due to its low incidence, data on this condition are limited.MethodsWe conducted a systematic review of the reported cases of CS by searching MEDLINE ...
Gianfranco Alicandro +2 more
exaly +4 more sources
Successful Treatment of Cepacia Syndrome [PDF]
a Departments of Paediatrics and Child Health, University of Otago, Wellington, Wellington Hospital, Capital and Coast Health, PO Box 7343, Wellington 6015, New Zealand b Queensland Paediatric Infectious Diseases Laboratory, Queensland Children's Medical Research Institute, Royal Children's Hospital, School of Medicine, University of Queensland ...
Timothy J. Kidd +2 more
exaly +5 more sources
‘Cepacia Syndrome’ With Burkholderia multivorans, 9 Years After Initial Colonization [PDF]
A 16-year-old boy with cystic fibrosis developed 'cepacia syndrome' 9 years after the first isolation of Burkholderia multivorans. It is important to recognise that 'cepacia syndrome' is not restricted to those infected with genomovar type III strains and that rapid, irreversible clinical decline can occur many years after the 1st isolation of ...
Steven Conway, K Brownlee, M Denton
exaly +3 more sources
Successful Treatment of Cepacia Syndrome With Combination Nebulised and Intravenous Antibiotic Therapy [PDF]
We report the case of successful treatment of a 31-year-old lady with cystic fibrosis and an en-bloc liver-pancreas transplant, who developed cepacia syndrome on a background of chronic infection with the ET12 epidemic strain of Burkholderia cenocepacia.
Andrew M Jones, A K Webb, M E Dodd
exaly +3 more sources
Successful Treatment of Cepacia Syndrome With a Combination of Intravenous Cyclosporin, Antibiotics and Oral Corticosteroids [PDF]
Burkholderia cepacia complex (BCC) is a group of 17 closely related bacterial species that can cause pulmonary infection in patients with cystic fibrosis (CF). The clinical manifestations of BCC infection are varied but can include cepacia syndrome, which is a rapidly progressing necrotising pneumonia with an almost universally fatal outcome. We report
Francis J Gilchrist +2 more
exaly +3 more sources
Successful Lung Re-Transplant in a Patient With Cepacia Syndrome Due to Burkholderia ambifaria [PDF]
Chronic airway inflammation and infection drive morbidity and mortality among patients with cystic fibrosis (CF). While Haemophilus influenzae and Staphylococcus aureus predominate in children, the prevalence of Pseudomonas aeruginosa increases as patients age.
Rajat Walia +2 more
exaly +3 more sources
Bacteria-Associated Haemophagocytic Syndrome and Septic Pulmonary Embolism Caused by Burkholderia cepacia Complex in a Woman With Chronic Granulomatous Disease [PDF]
Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized by recurrent infections with certain types of bacteria and fungi. Presented herein is the case of a 29 year old woman with CGD who suffered from bacteria-associated haemophagocytic syndrome and a septic pulmonary embolism following a uterine infection and sepsis, caused by ...
Michi Hisano +2 more
exaly +3 more sources
Traditionally known as a nosocomial organism and preponderance to infect the immunocompromised patients or withpreexisting structural damage in lung parenchyma1, Burkholderia cepacia infection in an apparentlyimmunocompetent host in ICU settings is not very commonly heard of.
Chinmay Saha Podder +4 more
exaly +2 more sources
Related searches:
Hemophagocytic syndrome, splenic microabscesses and pulmonary cavitary lesions were presented in a 17-month-old boy with prolonged fever, hepatosplenomegaly and a history of tuberculous lymphadenitis. Clinical course mimicked tuberculosis. Blood cultures were negative.
Sayomporn, Sirinavin +5 more
openaire +2 more sources
Efficacy of Ivacaftor in a Child with Cystic Fibrosis, End-Stage Lung Disease, and Cepacia Syndrome
Pediatric Allergy, Immunology, and Pulmonology, 2012Ivacaftor is a small-molecule potentiator of the cystic fibrosis (CF) transmembrane-conductance regulator and was recently approved for use in CF patients with at least one copy of the G551D mutation. Two clinical trials have proven its efficacy in CF patients 6 years of age and older with mild-to-moderate lung disease.
Walter A. Castro-Elias +4 more
openaire +1 more source

